XOMA Corporation (XOMA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 21, 2025, to be held virtually, with voting on six key proposals including director elections, auditor ratification, reincorporation, bylaw amendments, equity plan updates, and potential adjournment.
Board recommends approval of all proposals, citing governance best practices, cost savings, and alignment with shareholder interests.
Forward-looking statements highlight anticipated benefits from reincorporation, equity plan changes, and ongoing governance enhancements.
Voting matters and shareholder proposals
Proposal 1: Election of seven directors to serve until 2026.
Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for 2025.
Proposal 3: Reincorporation from Delaware to Nevada, expected to yield cost savings and reduce litigation risk.
Proposal 4: Authorization for the Board to unilaterally amend bylaws, aligning with market practice.
Proposal 5: Amend and restate the 2010 Long Term Incentive and Stock Award Plan, increasing share pool by 880,000 shares and updating plan terms.
Proposal 6: Adjournment of the meeting if additional proxy solicitation is needed.
Board of directors and corporate governance
Board consists of seven members, with annual elections and a focus on diversity and relevant industry experience.
42% of directors self-identify as female, 14% as racially/ethnically diverse, and 14% as LGBTQ+.
Board leadership is separated between an independent Chairman and the CEO.
Standing committees include Audit, Compensation, and Nominating & Governance, all composed of independent directors.
Latest events from XOMA Corporation
- Royalty receipts rose 68% and the portfolio doubled, fueling strong cash flow and profitability.XOMA
Q4 202518 Mar 2026 - Diversified royalty portfolio, strong cash flow, and major pipeline catalysts ahead.XOMA
Leerink Global Healthcare Conference 202611 Mar 2026 - Diversified royalty portfolio, multiple phase III catalysts, and profitability targeted by 2027.XOMA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Biotech royalty aggregator grew to 100+ assets, with strong cash flow and key 2026 milestones ahead.XOMA
Corporate presentation2 Mar 2026 - Scalable royalty aggregation model targets early-stage biotech assets for sustained growth.XOMA
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Targets early-stage biotech royalties for high-margin, long-term cash flow and disciplined growth.XOMA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Early-stage asset focus and scalable model set to drive royalty growth and cash flow ramp.XOMA
Leerink Global Healthcare Conference 202526 Dec 2025 - Scalable royalty aggregation and disciplined capital deployment drive growth from 130+ biotech assets.XOMA
Jones Healthcare and Technology Innovation Conference 202523 Dec 2025 - Royalty aggregator leverages risk diversification and relationships to target high-margin growth.XOMA
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202523 Dec 2025